Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
32.12
-0.39 (-1.20%)
Jan 31, 2025, 4:00 PM EST - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for COLL stock have an average target of 43.8, with a low estimate of 37 and a high estimate of 50. The average target predicts an increase of 36.36% from the current stock price of 32.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for COLL stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold → Strong Buy Upgrades $46 | Hold → Strong Buy | Upgrades | $46 | +43.21% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +55.67% | Jan 10, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $37 | Hold | Reiterates | $37 | +15.19% | Oct 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $50 | Strong Buy | Maintains | $47 → $50 | +55.67% | Sep 5, 2024 |
| Piper Sandler | Piper Sandler | Hold Reiterates $39 → $37 | Hold | Reiterates | $39 → $37 | +15.19% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
641.84M
from 566.77M
Increased by 13.25%
Revenue Next Year
758.24M
from 641.84M
Increased by 18.14%
EPS This Year
6.30
from 1.29
Increased by 387.45%
EPS Next Year
6.77
from 6.30
Increased by 7.39%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 663.8M | 787.2M | 872.2M | |||
| Avg | 641.8M | 758.2M | 785.0M | |||
| Low | 613.8M | 722.7M | 710.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.1% | 22.6% | 15.0% | |||
| Avg | 13.2% | 18.1% | 3.5% | |||
| Low | 8.3% | 12.6% | -6.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.58 | 7.37 | 8.19 | |
| Avg | 6.30 | 6.77 | 7.44 | |
| Low | 5.95 | 5.90 | 6.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 409.1% | 16.9% | 21.0% | |
| Avg | 387.4% | 7.4% | 9.8% | |
| Low | 360.1% | -6.4% | -1.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.